ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0563

Clinical Features of Patients with SpA, with or Without IBD: Results from the METEOR Cohort

Manouk de hOoge1, Pedro M. Machado2, Sytske Anne Bergstra3, Maxime Dougados4, Clementina López Medina5, Victoria Navarro Compán6, Diego Benavent7, Denis Poddubnyy8, Levent kilic9, Philippe Carron10, Dirk Elewaut11, Filip Van den Bosch12 and Gaelle Varkas12, 1Dept. of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, 2Department of Rheumatology, University College London Hospitals NHS Foundation Trust; and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust; and Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 3LUMC, Leiden, Netherlands, 4Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, 5Reina Sofia University Hospital, Cordoba, Spain, 6La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, 7Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, CAMBRILS, Spain, 8Charite-Universitatsmedizin Berlin, Berlin, Germany, 9Dept. of Rheumatology, Hacettepe University, Ankara, Turkey, Ankara, Turkey, 10UZ Gent, Gent, Belgium, 11Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, 12Ghent University Hospital, Ghent, Belgium

Meeting: ACR Convergence 2024

Keywords: Inflammation, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: To investigate clinical features of SpA patients with and without IBD, identifying the patient group that would benefit from initiating therapy with efficacy in both SpA and IBD at the time of diagnosis of either entity.

Methods: Methods

The METEOR SpA database encompasses patients with a clinical diagnosis of SpA, exhibiting peripheral or axial disease. These patients were stratified based on the presence or absence of concomitant IBD, reported by the local investigator. Patient and disease characteristics, patient and physician reported outcomes, disease activity measures, physical functioning, prescribed treatment and local imaging assessments were collected. Presence of IBD was reported as current or past and was likewise used for the patient stratification. Comparisons of continuous outcomes between two groups were performed using Student’s t–test for independent samples or the Mann-Whitney U test (according to the distribution of data).

Results: We identified 11,589 SpA patients with available data on IBD, of which 7% of patients had concomitant IBD with mean symptom duration of 12±12 years at inclusion in METEOR. Prevalence ranged from < 1% to 20% across 29 countries worldwide (fig 1). In SpA patients with IBD, male predominance was less pronounced, with marginally higher BMI versus those with SpA only (fig 2). Moreover, a marginally longer disease duration and diagnostic delay was observed. Lower prevalence of HLA-B27 and psoriasis was seen in the presence of IBD, even though uveitis rates were found to be higher. No differences were noted regarding the prevalence of dactylitis, enthesitis or elevated CRP. Patients showed similar disease activity, reflected by BASDAI, ASDAS and both physician and patient VAS.

SpA patients with IBD seemed to exhibit more structural damage of the sacroiliac (SI) joints, as indicated by modified NY criteria, compared to those without IBD. Similarly, higher BASFI was reported. However, the presence of inflammatory lesions on MRI (ASAS definition), as well as the presence of syndesmophytes was found to be similar among groups, although data on the latter was scarce.

Conclusion: In the METEOR database, SpA patients with IBD, as opposed to those without IBD, were less frequently male and more frequently HLA-B27 negative, yet demonstrated higher rates of uveitis and lower rates of psoriasis. These results support the lower rates of HLA-B27 and psoriasis described in Belgian SpA patients with IBD. [1] Despite the limitations of the interpretation of structural damage on conventional radiograph, SpA patients with concomitant IBD exhibited more structural damage on SI joints compared to patients without IBD, possibly mirroring gut inflammation as a risk factor for evolution into radiographic axSpA. Nevertheless, these patients also exhibited longer symptom duration. In light of evolving, occasionally more selective, therapeutic agents, identifying SpA patients at risk of developing IBD at the time of diagnosis would prevent unnecessary therapy cycling. Further research should focus on identifying baseline risk factors in large prospective studies.

Supporting image 1

Supporting image 2


Disclosures: M. de hOoge: None; P. Machado: AbbVie, 12, Personal fees, Bristol Myers Squibb, 12, Personal fees, Celgene, 12, Personal fees, Eli Lilly, 12, Personal fees, Galapagos, 12, Personal fees, GSK, 12, Personal fees, Janssen, 12, Personal fees, MSD, 12, Personal fees, Novartis, 12, Personal fees, Orphazyme, 12, Personal fees, Pfizer, 12, Personal fees, Roche, 12, Personal fees, UCB Pharma, 12, Personal fees; S. Bergstra: Pfizer, 5; M. Dougados: AbbVie, 2, 5, 6, Eli Lilly, 2, 5, 6, Merck, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB Pharma, 2, 5, 6; C. López Medina: AbbVie, 2, 5, 6, Eli Lilly, 2, 5, 6, Janssen, 6, MSD, 6, Novartis, 2, 5, 6, UCB Pharma, 2, 5, 6; V. Navarro Compán: AbbVie, 1, 6, Bristol-Myers Squibb(BMS), 2, 6, Eli Lilly, 2, 6, Fresenius Kabi, 2, 6, Galapagos, 2, 6, Janssen, 2, 6, MoonLake, 2, 6, Novartis, 2, 6, Pfizer, 1, 6, Roche, 2, 6, UCB, 2, 6; D. Benavent: Bristol-Myers Squibb(BMS), 1, Eli Lilly, 6, Janssen, 6, Savana Research, 12, Part-time work, UCB, 6; D. Poddubnyy: AbbVie, 2, 5, 6, Biocad, 2, Bristol-Myers Squibb(BMS), 2, 6, Eli Lilly, 2, 5, 6, Gilead, 2, MSD, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Samsung Bioepis, 2, UCB, 2, 6; L. kilic: AbbVie, Novartis, Pfizer, UCB Pharma, Celltrion, Amgen, 6; P. Carron: None; D. Elewaut: None; F. Van den Bosch: AbbVie/Abbott, 2, 6, Amgen, 6, Eli Lilly, 2, Fresenius Kabi, 6, Galapagos, 2, Janssen, 6, Novartis, 6, UCB, 6; G. Varkas: AbbVie/Abbott, 1, 2, 5, 6, Amgen, 6, Celltrion, 5, Eli Lilly, 6, Janssen, 6, UCB, 1, 2, 6.

To cite this abstract in AMA style:

de hOoge M, Machado P, Bergstra S, Dougados M, López Medina C, Navarro Compán V, Benavent D, Poddubnyy D, kilic L, Carron P, Elewaut D, Van den Bosch F, Varkas G. Clinical Features of Patients with SpA, with or Without IBD: Results from the METEOR Cohort [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/clinical-features-of-patients-with-spa-with-or-without-ibd-results-from-the-meteor-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-features-of-patients-with-spa-with-or-without-ibd-results-from-the-meteor-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology